<DOC>
	<DOCNO>NCT01271582</DOCNO>
	<brief_summary>The purpose study investigate association UGT1A1 polymorphisms neutropenia diarrhea Korean patient advance colorectal gastric cancer treat FOLFIRI regimen .</brief_summary>
	<brief_title>Investigation Association Between UGT1A1 Polymorphisms Irinotecan Toxicity Korean Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Subjects meet follow criterion participate trial . Histologically confirm colorectal gastric cancer patient chemonaive fail 1st line chemotherapy Subjects expect receive toxicity test least FOLFIRI treatment . Aged 18 year old . ECOG performance status ≤ 2 . Anticipated life expectancy ≥ 3 month . Clinically acceptable function bone marrow , kidney liver function . 1 . ANC ≥ 1500/mm3 platelet count ≥ 100,000/mm3 2 . Serum total bilirubin ≤ 1.5 x ULN , alkaline phosphatase ≤ 2.5 x ULN , Serum ALT AST ≤ 2.5 x ULN ( Serum ALT AST ≤ 5 x ULN , liver metastasis present ) 3 . Serum creatinine ≤ 1.5 mg/dL CLcr &gt; 60 ml/min Subjects whose write informed consent obtain prior participation trial . Subjects meet follow criterion include trial . Pregnant breast feed woman Serious concurrent complication , severe active infection . Subjects chronic diarrhea , paralytic ileum , pulmonary fibrosis pneumonia interstitialis Subjects epilepsia severe psychiatric disorder . Subjects regard unsuitable trial investigator . Subjects participate clinical trial Subjects receive prior chemotherapy include irinotecan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Colorecatal cancer</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>UGT1A1</keyword>
	<keyword>Neutropenia</keyword>
</DOC>